Teva Pharmaceutical ( (TEVA) ) has provided an update.
Teva Pharmaceutical Industries has appointed Chen Lichtenstein as a new independent Board member, effective December 1, 2024. With a robust background in financial leadership and strategic roles at Syngenta Group and Goldman Sachs, Lichtenstein brings a wealth of expertise to Teva. His appointment reflects Teva’s strategic focus on enhancing its leadership with seasoned professionals in the financial and agricultural sectors.
Find detailed analytics on TEVA stock on TipRanks’ Stock Analysis page.
Trending Articles
- M&A News: Paramount’s (NASDAQ:PARA) Merger with Skydance May Get Delayed
- Ford (NYSE:F) Cuts Hours At German EV Plant
- Did Intel (NASDAQ:INTC) Win the “Server Recession?”
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
